KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.
Killer immunoglobulin-like receptors (KIRs) on natural killer cells (NKs) recognize groups of human leukocyte antigen (HLA) class I alleles. Cells without an inhibitory HLA ligand may trigger NK activation. Reduced risk of relapse has been reported in malignant hematologic diseases after haploidentical transplantation when HLA ligands against the inhibitory KIRs present in the donor were absent in the recipient. We performed haploidentical transplant in three children with refractory solid tumors. Our results showed that beneficial antitumor effects could be observed in the presence of inhibitory KIR-HLA mismatch. These preliminary results suggest a possible association between disease control and NK cell alloreactivity.
Pérez-Martínez
Antonio
A
Department of Pediatric Hematology and Oncology, Hospital Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain. aperezm.hnjs@salud.madrid.org
Leung
Wing
W
Muñoz
Evangelina
E
Iyengar
Rekha
R
Ramírez
Manuel
M
Vicario
José Luis
JL
Lassaletta
Alvaro
A
Sevilla
Julián
J
González-Vicent
Marta
M
Madero
Luis
L
Díaz-Pérez
Miguel Angel
MA
D000293:Adolescent; D001859:Bone Neoplasms / Q000235:genetics / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D002675:Child, Preschool; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D015235:HLA-B Antigens / Q000235:genetics; D015236:HLA-C Antigens / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000637:transplantation; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary; D008297:Male; D009447:Neuroblastoma / Q000235:genetics / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D054340:Receptors, KIR / Q000235:genetics*; D012074:Remission Induction; D012208:Rhabdomyosarcoma / Q000235:genetics / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D012512:Sarcoma, Ewing / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D013736:Testicular Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy
D015235:HLA-B Antigens; D015236:HLA-C Antigens; D054340:Receptors, KIR